NutraFuels, Inc. fka NutraLife Biosciences, Inc. Explores New Delivery Systems with Pharmaceutical GMP Manufacturer

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc. fka NutraLife Biosciences, Inc. Explores New Delivery Systems with Pharmaceutical GMP Manufacturer

Coconut Creek, FL, Feb. 28, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc., fka NutraLife Biosciences, Inc. (“the Company” or “NutraFuels”) (OTCQB: NTFU) plans to explore additional options for delivery systems for its nutraceutical and wellness products and pharmaceutical delivery systems.

“We are excited to be exploring our capabilities in the life sciences space by engaging in the research and development of more formulations and enhanced delivery systems with an experienced cGMP pharmaceutical manufacturer,” said Edgar Ward, CEO and Founder of NutraFuels.

The Company plans to explore these various pharmaceutical formulations and delivery systems while utilizing the valuable experience of a cGMP pharmaceutical manufacturer.

The Company manufactures and distributes private label and its own branded products under its NutraHempCBD and NutraSpray brands. The Company’s product development, testing and research are conducted by four chemists under the supervision of Mr. Ward. The Company manufactures 100% of its products at its FDA registered facility in accordance with GMP standards.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). As reported in its Form 8-K filed with the SEC on November 13, 2018, the Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. The Company’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements

This communication contains statements of a forward-looking nature about NutraFuels, Inc. (the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraFuels, Inc. Tests Confirm High Quality Proprietary Ultra Shear Technology Platform

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc. Tests Confirm High Quality Proprietary Ultra Shear Technology Platform

Coconut Creek FL, Feb. 22, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc. fka NutraLife BioSciences, Inc. (OTCQB: NTFU) (NTFU) and Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI) (together, the “Companies”), in a joint venture, today announce that analytical tests on Hemp-derived CBD oil processed by PBI’s Ultra Shear Technology™ (UST) platform confirm that: (i) UST processing results in the development of a true CBD oil nanoemulsion, and (ii) CBD is neither lost nor modified during the UST process (> 99% recovery).

The proprietary UST platform combines ultra-high pressure with extreme shearing forces to create very small, nano-scale mixtures of fluids that otherwise do not mix, resulting in a highly stable homogenized solution called nanoemulsions.

Dr. Vera Gross, Senior Scientist R&D at PBI, commented: “To determine if the UST process resulted in a loss or modification of CBD during processing, we enlisted the help of our collaborator NutraFuels, Inc. NTFU has an FDA-inspected, highly-qualified analytical laboratory with state-of-the-art equipment and well-trained chemists with years of experience in laboratory testing.”

For many oil-based nutritional and therapeutic products, such as CBD-infused nutraceuticals, nanoemulsions offer superior water solubility and increased bioavailability for improved absorption. Consequently, there is a significant need to develop reliable, scalable methods to process CBD oil into high-quality nanoemulsions, with minimal loss of CBD during the process.

Mr. Cooper Dodd, an R&D Scientist at NTFU, said: “Using a powerful laboratory method called HPLC to measure the concentrations of CBD and potential impurities, we determined that no appreciable amount of CBD was lost during the UST process. These results compare well to our standard processing method of ultrasonication, which can carry a risk of measurable loss of CBD, and sometimes create the appearance of impurities if not performed properly. While there is more work to be done, as a nutraceutical manufacturer with products already on the market, we see these results as a robust leap towards better optimization of our CBD-enhanced products.”

Dr. Gross, Director of Applications Development from PBI, added: “To determine if UST processing of CBD oil generates true nanoemulsions, we asked an independent, university-affiliated laboratory to determine the size of oil droplets in post-UST processed material using a universally-accepted sizing method called DLS. Their results showed that post-UST processed oil droplets were approximately 65 nm in size, well within the range of 20-200 nm generally accepted as defining a true nanoemulsion (Nano- and Microscale Drug Delivery Systems, 2017).”

Professor Keith Warriner, Professor of Food Science at the University of Guelph, and a recognized expert in the cannabis industry, commented: “The data disclosed today on UST-generated nanoemulsions of CBD oil are very impressive. Creating nanoemulsions of CBD oil with full preservation of CBD throughout the process, while not generating impurities, remains a significant challenge in the industry. These data offer great promise to the future.”

Professor Warriner continued: “Although there is great excitement over CBD-infused edibles and beverages, and rightfully so, I believe that CBD-infused topicals may be an even greater market for CBD products in the near future. However, to be successful, it is imperative that topicals be highly stable, bioavailable and readily absorbent nanoemulsions. After a review of the data released today, the UST process appears to be a leading candidate to fill that need.”

Dr. Bradford A. Young, Chief Commercial Officer of PBI, commented: “We were very excited to share the news just last week of PBI’s visually obvious successful production of water-soluble CBD Oil. However, the addition of these scientific validations of our successful achievement of creating nanoemulsions by the UST platform, and our preservation of CBD levels all the way through to the finished product are frankly the crowning touch to the news of these accomplishments.  We believe our proprietary Ultra Shear Technology will be a pivotal change agent strongly affecting the future of many major existing product areas, spanning foods, nutraceuticals, therapeutics, cosmetics, lubricants, paints, and other industries.”

About NutraFuels, Inc.

NutraFuels, Inc. fka NutraLife BioSciences, Inc. was founded in 2010 and has evolved into a branded and private label developer, distributor and Food and Drug Administration registered (FDA) manufacturer. NTFU’s products include a range of nutraceutical, wellness, and CBD products as well as a cosmetics line. NutraFuels’ manufacturing process received the Good Manufacturing Processes Standard (GMP) certification. Its products adhere to high manufacturing standards throughout every step of the manufacturing and extraction process. NTFU’s product testing and research and development are conducted by four chemists under the direction of NTFU’s founder and Chief Executive Officer, Edgar Ward.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO ’s primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, PBIO is actively expanding the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired protein disaggregation and refolding technology from BaroFold, Inc. to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward-Looking Statements

This press release contains forward-looking statements about NutraFuels, Inc. and Pressure BioSciences, Inc. (collectively the “Companies”). These statements relate to future events or the Companies’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause each of the Companies industry results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Companies have based these forward-looking statements largely on their current expectations and projections about future events and financial trends that the Company believes may affect their respective financial condition, results of operations, business strategy, and financial needs. These statements are only predictions based on each of the Companies current expectations and projections about future events. Investors should not place undue reliance on these statements. In evaluating these statements, Investors should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause the Companies’ actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in each of the Companies’ Annual Reports and other reports filed from time to time with the Securities & Exchange Commission (SEC). More detailed information about these risk factors are set forth in the Companies’ filings with the SEC. The Companies encourage Investors to review these risk factors. The Companies undertake no obligation to update any of the information included in this release, except as otherwise required by law.

HEMP-DERIVED CBD STOCKS

Sales of legal marijuana including hemp-derived CBD products are expected to skyrocket 145% in the next four years taking the industry from $10 billion last year to $24.5 billion by 2021 according to moneymorning.com. It’s not surprising given this information that some investors are focusing on CBD stocks.

According to Project CBD, CBD is a cannabis compound that does not make people feel “stoned”. Currently, CBD is enjoying a surge in popularity. Some investors are looking for CBD companies offering products made from CBD such as oils, topical treatments, and oral sprays.

NutraFuels, Inc., a CBD Stock company manufactures and distributes a line of CBD-based nutraceutical products. They are dedicated to bringing the highest quality, most beneficial, effective nutrients and delivery systems to the market. With over 35 years experience in nutritional supplementation, NutraFuels knows the importance of products that are natural and highly effective in maintaining one’s healthy lifestyle.

“We are preparing for an increase in business as we see the demand for CBD products growing,” said Edgar Ward, CEO, and President of NutraFuels, Inc. “We want to get our nutraceutical products in the hands of as many people as possible because we believe that we have some of the best products and manufacturing processes available in today’s CBD market.”

NutraFuels is also a fully-reporting CBD company with a class of securities registered with the SEC and can be found under stock symbol NTFU. In 3 years, Nutrafuels has seen an incredible increase in earnings, from $250K in 2016 to $3 million (projected) in 2018. As the demand for CBD products continues to grow, NutraFuels is prepared to increase its  production and CBD stock and inventory to meet demand it expects from future passage of the Farm Bill. The Farm Bill holds potential promising news for CBD Stocks and CBD manufacturers and distributors like NutraFuels. CBD Stock companies are anxiously awaiting updates on the passage of the Farm Bill.


NutraFuels Inc. is a nutraceutical company with a line of CBD-infused products known by its in-house brand, NutraHempCBD. Using premium CBD hemp oil, its formulations are designed to promote overall health and wellness.  NutraFuels, Inc is a fully reporting company with a class of securities registered with the U.S. Securities & Exchange Commission (“SEC”). As reported in its Form 8-K filed with the SEC on November 13, 2018, NTFU recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.
* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward Looking Statements

This communication contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on  April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraFuels, Inc. Founds NutraDerma Technologies and Acquires Patented All-Natural Skin Patch For Deet-Free Mosquito Deterrent and Creates New Subsidiary, NutraDerma Technologies, Inc.

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc. Founds NutraDerma Technologies and Acquires Patented All-Natural Skin Patch For Deet-Free Mosquito Deterrent and Creates New Subsidiary, NutraDerma Technologies, Inc.

Coconut Creek, FL, Feb. 12, 2019 (GLOBE NEWSWIRE) — –via NEWMEDIAWIRE — NutraFuels, Inc. (NTFU), soon to be NutraLife BioScience, Inc.  (“NutraFuels” or the “Company”) has acquired a patent for a unique and natural formulation that deters insects including mosquitoes through a dermal delivery system patch. On January 28, 2019, NutraFuels founded a new wholly owned subsidiary, NutraDerma Technologies, Inc. (“NutraDerma”) to commercialize the patented dermal patch.

* This product is not intended to diagnose, treat, cure or prevent any disease.The all-natural insect deterrent dermal patch is the first planned product for NutraDerma. The patented patch uses natural ingredients such as Vitamin B1 to ward off insects. NutraFuels founded NutraDerma to commercialize the all-natural dermal mosquito patch upon compliance with applicable regulatory requirements.

NutraDerma plans to develop other nutraceutical, skin care, cosmetic and wellness dermal skin patches including vitamin supplement patches and various formulations designed to harness the benefits of combining key ingredients and technologies to support health and wellness. With the acquisition of its new patent, NutraDerma has taken its first step towards entering the bio life sciences market.

According to the American Mosquito Control Association (“AMCA”), there are more than one million Malaria-related deaths and 300 – 500 million cases are reported annually throughout the world. As the Center for Disease Control (“CDC”) reports, Zika is still a threat internationally as well.

NutraFuels, Inc is a fully reporting company with a class of securities registered with the U.S. Securities & Exchange Commission (“SEC”). As reported in its Form 8-K filed with the SEC on November 13, 2018, NTFU recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

Forward Looking Statements
This communication contains statements of a forward-looking nature about NutraFuels, Inc. fka NutraLife BioSciences, Inc., and its wholly owned subsidiary, NutraDerma Technologies, Inc. (the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that Company’s current expectations and projections concerning its ability to commercialize the patented insect dermal patch are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.